Chris is a Senior Consultant supporting a range of partnering and business development assignments. His experience includes market opportunity assessments, competitive landscape analyses, drug market modeling, technical feasibility, pipeline opportunity and commercial attractiveness assessments, Gap analyses, strategic development planning, and identification of strategic alliances for biotech and pharma to facilitate in-licensing and out-licensing of various technologies. Prior to Alacrita, Chris has 13 years of experience building and leading teams of scientists in research activities supporting target identification, cell-based and biochemical assay development, compound and CRISPR screening, AAV and lentiviral vectors, and lead identification and optimization that led to INDs and Phase 1 clinical trials for three separate small molecule drug programs. Chris has consulted for big pharma, startups and mid-sized pharmaceutical companies for 2.5 years.
Chris has a Ph.D. in Microbiology & Molecular Genetics from Harvard University, an M.M.Sc. from Harvard Medical School (an education encompassing the first two years of Medical School), and a B.A. in Biochemistry from Knox College. While at Harvard University, he co-discovered TRIM5α in rhesus macaques as a potent post-entry inhibitor of HIV infection. Over the years, he has been listed as an inventor on three patent applications, authored eight peer-reviewed publications in leading medical journals, and given fifteen conference presentations to top scientists in his field.